95 related articles for article (PubMed ID: 20727868)
41. Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy.
Nisselbaum JS; Bosl GJ; Golbey RB; Schwartz DC; Schwartz MK
Ann Clin Lab Sci; 1984; 14(3):179-88. PubMed ID: 6203466
[TBL] [Abstract][Full Text] [Related]
42. Unreliable immunoassays, patients' safety, and clinical research.
Lindstedt G; Frändberg S
Lancet; 2002 Jan; 359(9303):356-7. PubMed ID: 11830234
[No Abstract] [Full Text] [Related]
43. Potential error in an immunoradiometric kit for determining choriogonadotropin.
Rzasa PJ; Prokop EK; Caride VJ
Clin Chem; 1985 Nov; 31(11):1917-8. PubMed ID: 4053374
[No Abstract] [Full Text] [Related]
44. Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update.
Plüddemann A; Thompson M; Price CP; Wolstenholme J; Heneghan C
Br J Gen Pract; 2012 Mar; 62(596):e224-6. PubMed ID: 22429442
[TBL] [Abstract][Full Text] [Related]
45. Choriogonadotropin: now you see it--now you don't.
Travis JC; Dewhurst PB
Clin Chem; 1984 Feb; 30(2):334-5. PubMed ID: 6692554
[No Abstract] [Full Text] [Related]
46. [Tighten up the quality requirements on pharmacy self-tests].
Asplund L
Lakartidningen; 2012 Nov 28-Dec 4; 109(48):2232. PubMed ID: 23330534
[No Abstract] [Full Text] [Related]
47. Limitations of tests for human chorionic gonadotropin.
Bagshawe KD
Lancet; 2000 Feb; 355(9205):671. PubMed ID: 10703795
[No Abstract] [Full Text] [Related]
48. Comment on the nature and specificity of Bayer Corporation and Chiron Diagnostics hCG immunoassays.
Cole LA; Abbott TJ; Armstrong EG
Clin Chem; 1998 Sep; 44(9):2001-2. PubMed ID: 9732997
[No Abstract] [Full Text] [Related]
49. Assessing the performance of point-of-care hemoglobin A1c systems.
Irvin B; Knaebel J; Simmons D
Clin Chem; 2010 Aug; 56(8):1359-60; author reply 1360-1. PubMed ID: 20511444
[No Abstract] [Full Text] [Related]
50. Optimal analytical performance for point of care testing.
Fraser CG
Clin Chim Acta; 2001 May; 307(1-2):37-43. PubMed ID: 11369335
[TBL] [Abstract][Full Text] [Related]
51. Managing QC and compliance with automated POCT management.
Hopley R; Sigman A; Carr K; Roberts J; Rogers B
MLO Med Lab Obs; 2011 Jul; 43(7):26, 28. PubMed ID: 21830656
[No Abstract] [Full Text] [Related]
52. Inappropriate Off-label Use of a Qualitative, Point-of-care hCG Device.
Nerenz RD; Gronowski AM; Grenache DG
West J Emerg Med; 2017 Feb; 18(2):324-325. PubMed ID: 28265335
[No Abstract] [Full Text] [Related]
53. [Gonadotropin loading test].
Yasuda M; Aono T
Nihon Rinsho; 1979 Jun; Suppl():2495-8. PubMed ID: 491198
[No Abstract] [Full Text] [Related]
54. Discordant hCG measurements in a patient with a carcinoma.
Remaley AT; Bulley M; Senior MB; Goodman DB
Clin Chem; 1989 Jun; 35(6):1259-60. PubMed ID: 2731351
[No Abstract] [Full Text] [Related]
55. In reply to: “Inappropriate Off-label Use of a Qualitative, Point-of-care hCG Device”.
Gottlieb M; Wnek K; Moskoff J; Christian E; Bailitz J
West J Emerg Med; 2017 Feb; 18(2):326. PubMed ID: 29911828
[No Abstract] [Full Text] [Related]
56. [Quality management of testing at bedside].
Nichols J
Klin Lab Diagn; 2009 May; (5):51-4. PubMed ID: 19537114
[No Abstract] [Full Text] [Related]
57. Quality assurance in diagnostic immunohistochemistry. A discipline coming of age.
Wick MR
Am J Clin Pathol; 1989 Dec; 92(6):844. PubMed ID: 2589252
[No Abstract] [Full Text] [Related]
58. Calibration of prolactin kits.
Hall CA; Lojewski RJ
Clin Chem; 1985 Jun; 31(6):1100-1. PubMed ID: 3995756
[No Abstract] [Full Text] [Related]
59. [Management of POCT Devices and Reagents].
Yamada O
Rinsho Byori; 2015 Feb; 63(2):218-23. PubMed ID: 26529973
[TBL] [Abstract][Full Text] [Related]
60. A point-of-care device for acute kidney injury: a fantastic, futuristic, or frivolous 'measure'?
Parikh CR
Kidney Int; 2009 Jul; 76(1):8-10. PubMed ID: 19528988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
